{"id":"W4251804183","doi":"10.1093/ibd/izy393.049","title":"01 DOSE ESCALATION WITH ORIGINATOR INFLIXIMAB IS MORE COMMON THAN STANDARD DOSING IN PEDIATRIC IBD – THE DEVELOP EXPERIENCE","year":2019,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Infliximab; Inflammatory bowel disease; Ulcerative colitis; Internal medicine; Observational study; Population; Dosing; Clinical trial; Disease; Pediatrics","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":{"n_in":0,"stratum":"about_only","weight":3321.24,"opus":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Registry analysis of infliximab dose escalation in pediatric IBD; clinical question."},"gpt":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"The registry study examines infliximab dosing in pediatric inflammatory bowel disease."},"grok":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Observational registry of infliximab dosing in pediatric IBD; clinical therapeutics."}},"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003683873,0.0001430102,0.0003701804,0.0005415042,0.0003264227,0.001472314,0.0003367333,0.0004194205,0.002331545],"category_scores_gemma":[0.01444299,0.0001888174,0.0006074827,0.001374374,0.0004103868,0.001217558,0.000758072,0.001087921,0.0003749409],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009845167,"about_ca_system_score_gemma":0.0008072678,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001598106,"about_ca_topic_score_gemma":0.002989762,"domain_scores_codex":[0.9958724,0.001566895,0.0005026831,0.0007214477,0.001039024,0.0002975349],"domain_scores_gemma":[0.9859278,0.003216845,0.00819496,0.001217829,0.0007383957,0.0007042214],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005525363,0.0001643284,0.9590369,0.0000935668,0.0001163314,0.0003213184,0.000325985,0.0001240841,0.0003113494,0.0004572443,0.002413203,0.03608316],"study_design_scores_gemma":[0.0001471758,0.001402382,0.9707638,0.0001877468,0.0002122438,0.003923583,0.001008498,0.0005612327,0.001149099,0.0002644757,0.02035944,0.00002032984],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878165,0.002442621,0.0007864338,0.0009697617,0.0000370931,0.0000591445,0.001743933,0.00003284105,0.006111677],"genre_scores_gemma":[0.9936907,0.001860431,0.0007149832,0.0009779662,0.0001229594,0.00004517518,0.001846288,0.00002957435,0.0007118996],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003683873,"threshold_uncertainty_score":0,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00578187929526759,"score_gpt":0.2422013737998419,"score_spread":0.2364194945045743,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}